Senior or Principal Scientist, Formulation and Process Development

We are seeking a Senior or Principal Scientist, Formulation and Process Development, who will report to the Director, Pharmaceutical Development. You will focus on leading formulation and process development work supporting Celcuity’s drug product development and product lifecycle management. The Sr./Principal Scientist role will join a collaborative Pharmaceutical Development group focused on advancing Celcuity’s lead drug candidates. The Sr./Principal Scientist will lead formulation and process development projects for novel formulations targeted toward existing and new indications, as well as projects supporting Celcuity’s existing oncology drug product.

• Lead projects to support development of novel and existing formulations, spanning the product lifecycle including pre-formulation, dosage form selection, formulation development, process development, and manufacturing scale-up.
• Design, execute, and interpret formulation and process development experiments in an outsourced environment at contract laboratories and CDMOs.
• Identify and vet new contract organizations to support formulation and process development.
• Help define & execute the project plans for formulation lifecycle management.
• Support writing technical sections for intellectual property and regulatory filings.
• Develop and maintain an in-depth knowledge of formulation development trends, techniques, and technologies.
• Serve as a subject matter expert for formulation development within the Pharmaceutical Development group and the broader Celcuity team.
• Summarize, document, and present information to subgroup, group, and cross-functional audiences.
• Other duties as assigned.

• Ph.D/M.S./B.S. in Pharmaceutical Science, Chemical Engineering, Chemistry, Biochemistry, Biochemical Engineering, or related fields.
• 7+ years of experience in pharmaceutical development (preferred 4+ years industry experience for Ph.D; 5+ years for M.S.; 7+ years for B.S.).
• Demonstrated experience with formulation development and drug product development, preferably for small molecule drugs.
• Deep understanding of formulation techniques & considerations for sterile, parenteral dosage forms. Knowledge of other dosage forms (e.g., for ophthalmic or oral) is beneficial.
• Experience with drug device combination products for injectable drug products (e.g., prefilled syringes, autoinjectors) is preferred. Knowledge of other dosage form delivery techniques (e.g., for ophthalmic) is beneficial.
• Technical expertise in formulation strategies and processes specifically tailored to poorly water-soluble APIs is preferred. Subject matter expertise in one or more of these areas is highly desirable:
  • Nano-milling and nanosuspension formulation.
  • Micro/nano-emulsions.
  • Salt formation and salt screening/selection.
  • Complexation and co-solvency using cyclodextrins or co-solvents.
  • Lyophilization
• Experience with physicochemical characterization methods for drug substances and drug products.
• Experience with preclinical study support and early-stage formulation development.
• Excellent written and verbal communication skills, with ability to influence and build credibility at all levels.
• Strong interpersonal skills for interacting with colleagues across various levels and functions.
• Attention to detail and ability to manage multiple processes and documentation requirements.
• Strong technical and analytical skills with advanced knowledge in MS Office products.
• Ability to work in a team or independently as required.
• Outstanding organizational skills with the ability to prioritize.
• Demonstrated independent and sound decision-making skills; ability to think critically and make decisions in a fast-paced environment.
• Flexible and willing to learn; able to adapt to business and site needs in a dynamic environment.
• Maintain a positive, approachable and professional attitude.

Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to…